For AML patients,[[Inline Image]][[Inline Image]] enasidenib is an inhibitor of mutant IDH2 proteins used to treat newly diagnosed mutant-IDH2 AML patients (Pollyea et al., 2019). This evidence concerns the gene IDH2 and acute myeloid leukemia.